IL6 and metabolic syndrome: Systemic inflammation, evidenced by increased levels of pro-inflammatory cytokines such as IL-6 and TNF-α, together with biomarkers of endothelial dysfunction such as PAI-1 and CRP, demonstrate a chronic inflammatory state present in MetS.